While employers fall on a spectrum when it comes to knowledge and understanding of biosimilars, there does remain a need to educate them, as well as for them to educate their employees, said Margaret Rehayem, vice president, National Alliance of Healthcare Purchaser Coalitions.
While employers fall on a spectrum when it comes to knowledge and understanding of biosimilars, there does remain a need to educate them, as well as for them to educate their employees, said Margaret Rehayem, vice president, National Alliance of Healthcare Purchaser Coalitions.
Transcript
How comfortable and confident in biosimilars are employers to push for these products over the reference? Are you still needing to provide education so employers understand the benefits of biosimilars?
There is still a need for education for employers. I think, employers really fall across the spectrum when we're talking about biosimilars. Some of them have actually not only put them on formulary but are willing to go to their health plan, their [pharmacy benefit manager] and actually say, “This is what I want.” And then we've had employers that are still trying to figure out where biosimilars can or should show up in their contract. There's really this broad spectrum right now that we're working with. Therefore, I think there still is a need for education.
We actually recently completed a learning collaborative where we had that broad spectrum within the same collaborative. It was a very exciting time just to hear those that were more well versed in those that were still learning willing to have discussions with one another on this topic. We're still going to continue to move forward with education and meet our coalitions where they're at with their members.
Do employers need to provide more education for employees on biosimilars, and what has that process looked like?
It's interesting, you bring that up, because this was a common concern for many of the employers that we've talked to is being able to communicate the right information that's out there. They're very concerned about the direct-to-consumer advertising is happening now with a lot of different types of drugs. They have to not only put the right information out there, but they have to counteract some of the misinformation that's out there about drugs. It's something that I think employers are very concerned about. They do want to get the right information out there. But they also need to make sure that they're coordinating with what they do have on formulary, so that they're giving the best information to their employees and families.
CMS' 340B Repayment Proposal May Harm Vulnerable Hospitals, Reward Those With Higher Revenues
April 26th 2024The 340B hospitals not receiving an offsetting lump-sum payment from CMS following 2018-2022 cuts later ruled unlawful are disproportionately rural, publicly owned, and nonacademic, according to a new study.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
The Federal Trade Commission's (FTC's) vote to ban most employers from issuing and enforcing noncompete clauses could have varying impacts on the health care workforce; federal regulators vastly under-enforced antitrust laws in the hospital sector during the last 2 decades, resulting in increased health costs; the FDA recently found genetic evidence of the H5N1 bird flu virus in pasteurized commercially purchased milk.
Read More
What We’re Reading: Abortion Privacy Rules; Alzheimer Drug Hurdles; Nursing Home Staffing Overhaul
April 23rd 2024New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.
Read More